Evidence map›Paper›PMID 34835785›Full record

ReviewNanomaterials (Basel, Switzerland)2021

The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors.

Kyle M Pierce, William R Miklavcic, Kyle P Cook, Mikayla Sweitzer Hennen, Kenneth W Bayles, Michael A Hollingsworth, Amanda E Brooks, Jessica E Pullan, Kaitlin M Dailey

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
  12. Nanotechnology for Pediatric Retinoblastoma Therapy.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kyle M PierceBiomedical Sciences, Rocky Vista University, Parker, CO 80130, USA.
William R MiklavcicEppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Kyle P CookBiomedical Sciences, Rocky Vista University, Parker, CO 80130, USA.
Mikayla Sweitzer HennenBiomedical Sciences, Rocky Vista University, Parker, CO 80130, USA.
Kenneth W BaylesDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Michael A HollingsworthEppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Amanda E BrooksOffice of Research & Scholarly Activity, Rocky Vista University, Ivins, UT 84738, USA.ORCID 0000-0001-9785-5969
Jessica E PullanOffice of Research & Scholarly Activity, Rocky Vista University, Ivins, UT 84738, USA.
Kaitlin M DaileyEppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0001-8834-0293

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While many classes of chemotherapeutic agents exist to treat solid tumors, few can generate a lasting response without substantial off-target toxicity despite significant scientific advancements and investments. In this review, the paths of development for nanoparticles, oncolytic viruses, and oncolytic bacteria over the last 20 years of research towards clinical translation and acceptance as novel cancer therapeutics are compared. Novel nanoparticle, oncolytic virus, and oncolytic bacteria therapies all start with a common goal of accomplishing therapeutic drug activity or delivery to a specific site while avoiding off-target effects, with overlapping methodology between all three modalities. Indeed, the degree of overlap is substantial enough that breakthroughs in one therapeutic could have considerable implications on the progression of the other two. Each oncotherapeutic modality has accomplished clinical translation, successfully overcoming the potential pitfalls promising therapeutics face. However, once studies enter clinical trials, the data all but disappears, leaving pre-clinical researchers largely in the dark. Overall, the creativity, flexibility, and innovation of these modalities for solid tumor treatments are greatly encouraging, and usher in a new age of pharmaceutical development.

Indexed as

clinical trialsexosomesnanoparticlesoncolytic bacteriaoncolytic virusessolid tumors

Identifiers

PMID34835785
PMCPMC8623458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.